Brief: Cleveland Biolabs Q3 revenue $1.1 million versus $500,000

Statera Biopharma

14/11/2016 12:30

Nov 14 (Reuters) - Cleveland Biolabs Inc  CBLI.O : 
    * Cleveland Biolabs- in discussions with european medicines 
agency for pediatric investigational plan for entolimod as 
medical radiation countermeasure 
    * A proposed PIP was filed with EMA 
    * Qtrly net income per share, basic and diluted $0.10 
    * Cleveland biolabs reports third quarter 2016 financial 
results and development progress 
    * Q3 revenue $1.1 million versus $500,000 
 
Source text for Eikon:  ID:nMKWYKcjCa  
Further company coverage:  CBLI.O  
 
 ((bangalore.newsroom@thomsonreuters.com;))